512-64-1

中文名称醌霉素A

英文名称 QUINOMYCIN A

CAS 512-64-1

分子式 C51H64N12O12S2

分子量 1101.26

MOL 文件 512-64-1.mol

更新日期 2024/08/21 17:38:37

512-64-1 结构式

基本信息物理化学性质安全数据醌霉素A价格(试剂级) 常见问题列表

基本信息

中文别名

棘霉素
醌霉素A

英文别名

SK-302B
nsc526417
NSC 13502
ECHINOMYCIN
QUINOMYCIN A
echinomycina
Echinomycin >97%
Antibiotic A 654I
Echinomycin (NSC-13502)
EchinoMycin, Actinoleukin, 1491, 59266, X 948, X 53III

物理化学性质

熔点217-218℃

比旋光度D20 -310° (c = 0.86 in chloroform)

沸点1427.2±65.0 °C(Predicted)

密度1.0964 (rough estimate)

折射率1.6700 (estimate)

储存条件-20°C

储存条件2-8°C

溶解度溶于DMSO（高达5mg/ml）

酸度系数(pKa)9.38±0.70(Predicted)

形态白色固体

颜色白色至米色

Merck13,3531

稳定性可在-20°C下DMSO溶液中保存长达3个月

安全数据

危险性符号(GHS) GHS hazard pictograms

GHS06,GHS08

警示词危险

危险性描述H301+H311+H331-H361

防范说明P201-P202-P280-P301+P310-P302+P352+P312-P304+P340+P311

危险品标志T

危险类别码46-23/24/25

安全说明53-36/37/39-45

危险品运输编号UN 3462 6.1/PG 2

WGK Germany3

RTECS号JW5250000

F10

危险等级6.1(b)

包装类别III

海关编码2941900000

醌霉素A价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2025/02/08	HY-106101	醌霉素A Echinomycin	512-64-1	1mg	2880元

常见问题列表

生物活性

Echinomycin (Quinomycin A) 是一种有效的,细胞渗透性的低氧诱导因子-1 (HIF-1) DNA 结合活性的小分子抑制剂。Echinomycin 选择性抑制癌症干细胞，其 IC50 值为 29.4 pM。

体外研究

Echinomycin (0-10 nM; 16 hours; U251 cells) treatment significantly inhibits hypoxia-induced VEGF mRNA expression in a dose-dependent fashion. Echinomycin very potently inhibits hypoxic induction of luciferase expression in U251-HRE in a dose-dependent fashion with an EC ₅₀ of 1.2 nM.

RT-PCR

Cell Line:	U251 cells
Concentration:	0 nM, 0.625 nM, 1.25 nM, 5 nM, 10 nM
Incubation Time:	16 hours
Result:	Significantly inhibited VEGF mRNA expression induced by hypoxia in a dose-dependent fashion.

体内研究

Echinomycin (10 μg/kg; intravenous injection; for 40 days; NOD-SCID mice) treatment efficiently eradicates mouse lymphoma and serially transplantable human acute myeloid leukemia (AML) in xenogeneic model by preferential elimination of cancer stem cells (CSCs). HIF1α maintains mouse lymphoma CSCs by repressing a negative feedback loop in the Notch pathway.

Animal Model:	NOD-SCID mice received 1.8Gy of irradiation and i.v. injection with peripheral blood cells from patients AML-71 and AML-150
Dosage:	10 μg/kg
Administration:	Intravenous injection; for 40 days
Result:	Efficiently eradicated mouse lymphoma and serially transplantable human AML in xenogeneic model by preferential elimination of CSCs.